Eagle Wealth Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$372K Buy
1,421
+106
+8% +$27.2K 0.27% 71
2026
Q2
$331K Buy
1,315
+152
+13% +$32.7K 0.25% 74
2026
Q1
$253K Buy
1,163
+12
+1% +$2.66K 0.23% 83
2025
Q4
$263K Buy
+1,151
New +$262K 0.22% 76

Other funds holding ABBV

Eagle Wealth Advisors's ABBV Position: Q3 2026 in Review

Eagle Wealth Advisors increased its AbbVie (ABBV) stake by 8.1% in Q3 2026, buying an estimated $27.2K and bringing the position to 1,421 shares worth $372K. The position accounts for 0.27% of the portfolio, ranked #71.

Eagle Wealth Advisors first reported a position in ABBV in Q4 2025 and has held it in 4 quarters since. 4,285 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Eagle Wealth Advisors held 1,421 shares of AbbVie worth $372K as of Q3 2026.
  • Eagle Wealth Advisors bought 106 AbbVie shares in Q3 2026, an estimated $27.2K.
  • AbbVie made up 0.27% of Eagle Wealth Advisors's portfolio in Q3 2026, its #71 holding.
  • Eagle Wealth Advisors first reported a position in AbbVie in Q4 2025 and has held it in 4 quarters since.
  • 4,285 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Eagle Wealth Advisors's 13F filing for Q3 2026, filed 20 Oct 2026.